The RD1 Product

The RD1, which is based on RedDress’ proprietary patented technology, is the first wound care product which enables health care providers to produce in real time, in vitro whole blood clots, for use as a chronic wound care product. The RD1 has been developed to address the need for cost effectiveness and clinical effectiveness of wound care.

The RD1 preparation process takes 12 minutes and the RD1 Clot is then applied to the wound.

RD1

Published articles

Kushnir I, Kushnir A, Serena TE, Garfinkel D. Efficacy and safety of a novel autologous wound matrix in the management of complicated, chronic wounds: a pilot study. Wounds. 2016;28(9):317–327.
Click here to open article

Snyder RJ, Kasper MA, Patel K, Carter MJ, Kushnir I, Kushnir A, Serena TE. Safety and Efficacy of an Autologous Blood Clot Product in the Management of Texas 1A or 2A Neuropathic Diabetic Foot Ulcers: A Prospective, Multicenter, Open Label Pilot Study. Wounds: a compendium of clinical research and practice.‏ 2018
Click here to open article